Vifor Pharma

Vifor Pharma FCF Conversion

Delisted·Dec 22, 2022

The FCF Conversion Rate (FCF/EBITDA) of Vifor Pharma (VIFN.SW) as of Nov 3, 2026 is 213.78 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 10.90 % — a change of 1,861.11% (higher).

FCF Conversion

213.78 %

YoY

1,861.11%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Vifor Pharma is 2021 213.78 % . FCF Conversion Rate (FCF/EBITDA) of Vifor Pharma was 2020 10.90 % . It decreases by 1,861.11% higher compared to the previous year.

The Vifor Pharma FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2014
100.53 CHF
Jan 1, 2015
118.69 CHF
Jan 1, 2016
-10.37 CHF
Jan 1, 2017
-2.45 CHF
Jan 1, 2018
-53.94 CHF
Jan 1, 2019
244.25 CHF
Jan 1, 2020
10.90 CHF
Jan 1, 2021
213.78 CHF
The Vifor Pharma FCF Conversion history
YEARFCF ConversionYoY
213.78 %+1,861.11%
10.90 %-95.54%
244.25 %-552.84%
-53.94 %+2,101.82%
-2.45 %-76.38%
-10.37 %-108.74%
118.69 %+18.07%
100.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vifor Pharma Stock analysis

What does Vifor Pharma do? Vifor Pharma AG is a leading pharmaceutical company based in St. Gallen, Switzerland. The company has a long history and over 100 years of experience in the manufacturing of pharmaceutical products. It was founded in 1872 as Etablissements Gallois and has undergone various mergers and acquisitions. Today, it is part of the global Galenica Group and has branches in over 30 countries. Vifor Pharma AG focuses on the development and production of medications for the treatment of iron deficiency and kidney diseases. It diversifies its business across different market segments and geographic regions. The company's well-known products include iron preparations sold under different brands such as Ferinject, Injectafer, and Venofer, used for the treatment of iron deficiency anemia in both intravenous and tablet forms. another important business area for Vifor Pharma AG is nephrology, with a wide range of kidney and dialysis products available, including treatments for hyperphosphatemia and anemia in dialysis patients. To strengthen its innovation, the company has invested in partnerships, such as an exclusive license for the distribution of Vadadustat, an oral medication for the treatment of anemia in chronic kidney disease. Vifor Pharma AG has also invested in the digitalization and data-driven technologies, acquiring a stake in the Austrian company medisign GmbH in 2020 to expand its expertise in digital health and telemedicine. In terms of sustainability, the company aims to be carbon-neutral by 2025 and has implemented measures to reduce its CO2 footprint. With its long history, diverse portfolio of products and services, and investments in innovation and sustainability, Vifor Pharma AG is well-positioned for future success. Vifor Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vifor Pharma stock

FCF Conversion Rate (FCF/EBITDA) of Vifor Pharma is 213.78 % in 2021.

FCF Conversion Rate (FCF/EBITDA) of Vifor Pharma changed from 10.90 % to 213.78 %, representing a 1,861.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Vifor Pharma since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Vifor Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Vifor Pharma

All Key Metrics — Vifor Pharma